Roche starts Phase III Clinical Trial of Actemra

Roche announced to initiate a randomized, double-blind, placebo-controlled Phase III clinical trial
(COVACTA study) globally including the U.S., Canada and Europe to evaluate the safety and efficacy of
Actemra plus standard of care in hospitalized patients with severe COVID-19 pneumonia compared to
placebo plus standard of care.

Actemra is the first therapeutic antibody created in Japan by Chugai (part of the Roch group), and designed to block the activity of IL-6, a type of inflammatory cytokine


Published by verycalmcorona

Simple Belgian citizen. I am not a native english speaker.

%d bloggers like this: